A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations

Trial Profile

A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; WNT 974 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 25 Jul 2017 The trial is Completed in Spain (Global end date:2017-07-10),according to European Clinical Trials Database record.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Feb 2017 Planned End Date changed from 1 Jan 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top